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1. Introduction
Kinetic modelling is an important tool in Positron Emission Tomography (PET) which enables
us to study the kinetics of tracers. Two important applications of this technique are its use in
drug development and in the study of the neurochemistry of the brain. A major issue that
we encounter when using kinetic modelling is the selection of the model and understanding
its limits and pitfalls. Furthermore, the acquisition, reconstruction and processing of PET
data also affects the kinetic modelling thereof. Therefore, we define the following three main
objectives for the reader of this chapter:
• To understand how the acquisition, reconstruction and processing of data affects its kinetic
modelling.
• To understand the rationale, the limits and the pitfalls of each model.
• To understand how model selection can be performed.
2. Acquisition
The acquisition process can be roughly divided into four different parts:
1. Preparation and monitoring of the patient
2. Injection of the tracer
3. PET measurement
4. Sampling of blood (optional)
2.1 Preparation and monitoring of the patient
Most studies for quantification of tracer kinetics last for a relatively long time (typically 60-90
minutes). Therefore, it is important to pay attention to the comfort of the patient when he or
she is positioned in the scanner as well as to use elements which can reduce head movement
(e.g. a tape around the head to fixate it). Due to the optimal performance at the centre of the
scanner, the head needs to be positioned in the central part of the field of view. If needed,
monitoring can be performed during the acquisition (e.g. ECG or blood pressure). When the
EEG needs to be monitored, this gives rise to local hot spots at the location of the electrodes
and introduces a small positive quantification bias in the reconstructed image in voxels located
in the brain (Lemmens et al. (2008)). This is caused by metal artifacts from the CT used for
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attenuation correction. Algorithms for metal artifact reduction in CT can be used to reduce
this problem (De Man et al. (2000)).
It is noteworthy to mention that the position of the patient (typically head first, supine) should
be indicated when preparing the PET acquisition. This ensures the correct orientation of the
reconstructed images since in most cases, left/right cannot be reliably determined based on
the images alone (in contrast to cranial/caudal and anterior/posterior orientations).
2.2 Injection of the tracer
When injecting the subject with the tracer, a cannula has to be in place (typically in an arm
vein). Most often a bolus injection is given, sometimes in combinationwith a constant infusion
of the tracer over the time period of the study to obtain a faster equilibrium (Carson (2000)).
In most human PET (or SPECT) imaging studies, only a very small amount of ligand is
injected, often in the range of pico to nanograms. This usually requires a high specific
activity, i.e. the amount of radioactively labelled versus unlabelled molecules, at the time of
injection. E.g. if the specific activity of a ligand is 4TBq/mmol at injection time and if we
inject 400MBq, the total amount of ligand injected is 0.1µmol. When using certain tracers (e.g.
[11C]-Carfentanil, a highly potent and selective µ opioid receptor agonist) the total amount of
compound administered has to be lower than some predefined value (e.g. 0.03µg/kg body
weight in case of [11C]-Carfentanil), ensuring sub-pharmacological doses.
To know the exact amount of activity injected, the remaining dose after injection (rest dose)
should be measured as well as the exact time of dose measurement, injection time and rest
dosemeasurement. Accurate timing requires the same or cross-calibrated clocks. The effective
dose injected can be calculated as:
D = Di ∗ e
− ln(2)t1/2
(t0−ti)
− De ∗ e
− ln(2)t1/2
(te−t0)
(1)
in which D is the effective dose injected at time t0, Di is the dose measured before injection at
time ti and De is the rest dose after injection as measured at time te. The half-life of the tracer
is given by t1/2.
2.3 PET measurement
Several high resolution PET scanners are available on the market for which the performance
is well characterized. New clinical scanners typically operate as a PET-CT scanner in which
the CT can be used for attenuation correction. For this purpose, a low dose CT, limiting
the radiation exposure, is sufficient. However, there are still high resolution dedicated PET
scanners in operation which most often use 68Ga/68Ge or 137Cs sources for attenuation
correction. The CT or PET scan used to correct for attenuation, sometimes called the
transmission scan, is not performed simultaneously and therefore a mismatch between
the head position during the transmission scan and the emission scan (i.e. the actual PET
measurement) can occur. This will lead to artifacts and can give rise to large errors in the
modelling. Therefore it is recommended that the coregistration between the transmission and
the emission scans is explicitly evaluated by an expert. This can be done by reconstructing the
PET emission image without attenuation correction and simultaneously viewing it with the
reconstructed transmission scan.
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PET measurements used for kinetic modelling are dynamic measurements. Two strategies
are possible depending on the scanner: a list-mode acquisition or a dynamic acquisition
in which time frames have to be specified before the start of the acquisition. List-mode
acquisition has the major advantage that rebinning in frames can be done afterwards and -
if necessary - another rebinning scheme can be used. However, due to the large amount of
data (depending on the number of events and the length of the scan), the option of using
multiple rebinning schemes is not always feasible in practice. The frame definition actually
defines the sampling resolution of the dynamic PET study. Since we need to reconstruct every
frame, two properties should be kept inmind: a frame should contain enough events to ensure
a reliable reconstruction, and during a frame the distribution of the tracer should be more or
less constant. These two requirements are not met in the beginning of the acquisition and
a trade-off has to be chosen. Sampling is certainly not uniform with short frames in the
beginning and gradually longer frames towards the end. An example of a frame definition
used when performing a 60 minutes [11C]-Flumazenil (a GABA-A antagonist) acquisition is 4
x 15s, 4 x 60s, 2 x 150s, 10 x 300s.
Since dynamic PET measurements are long, motion correction should be applied. First, by
paying attention to patient comfort when positioning them in the scanner, by fixating the
head, and by giving adequate instructions beforehand, major movements can be avoided.
Second, coregistration of the different frames can be performed to correct for small movements
(see later). Some groups are currently investigating how one can use tracking devices (e.g.
Montgomery et al. (2006)) or, in case of the new MRI-PET scanners, simultaneous MRI
scanning (Catana et al. (2011)) to continuously monitor any movement and to correct the list
mode using these measurements. This is still work in progress but the initial results look
promising.
Besides the frame definition, which only in case of list mode data can be changed after
the acquisition, a number of settings are irreversible, i.e. they cannot be changed after the
measurement. These are the time coincidence window, energy window, settings for scatter
and random measurements, measurements for attenuation, start and duration of the scan,
etc. Corrections for randoms, scatter and attenuation are necessary in brain imaging and
are relatively easy to perform. Scatter correction has an impact on the final results but few
studies have been done to quantify this. Attenuation correction is typically done when
quantification is necessary but when using a PET transmission scan, this might add additional
noise from the transmission scan through propagation into the reconstruction of the emission
data. Nowadays, this is much less of a problem when using CT for attenuation correction
since it is less noisy than a PET transmission scan.
Since often a bolus injection is given, dead time can be significant in the first minute. Adequate
dead time correction is necessary in order to correctly measure the high initial activity.
Therefore, the dead time correction available on the system should be well characterized.
The start and duration of the scan depend on the tracer and its kinetics as well as on the model
that will be applied to determine the physiological parameters. In many applications it is
common practice to start the scan at the time of injection although, for simplified methods, the
scan can be started at later a time point when equilibrium is approached. The duration of the
scan determines the amount of data generated. Furthermore, the duration is also determined
by the system under study: we assume that the physiological and metabolic processes which
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affect our measurement are more or less constant for the duration of the measurement, unless
we explicitly want to manipulate these processes in e.g. activation studies.
Importantly, it is necessary to correct for decay of the isotope unless one takes this into account
explicitly in the models. In this chapter we assume that decay correction has been performed.
2.4 Sampling of blood
A number of kinetic models that are commonly used in PET require the sampling of arterial
blood to determine the arterial blood or plasma concentration which indicates how much
tracer is available for uptake in the brain. This can be done by measuring radioactivity of the
blood/plasma samples with a well counter and scaling this number by the volume measured.
A major problem that arises with some tracers is that radioactive metabolites are formed
which are also detected and indistinguishable from intact tracer, since we measure the isotope
attached to a molecule and not the molecule itself. Often metabolites are formed outside the
brain and do not cross the blood-brain-barrier. In such a case, the input function can easily
be corrected by multiplying it with the intact fraction of the tracer at each time point. The
intact fraction can be obtained by taking blood samples at different time points and analyzing
them with high-performance liquid chromatography (HPLC) which separates intact tracer
from metabolites based on different retention times (due to different chemical interactions) in
a column .
For this procedure, it is required that the blood samples have a larger volume for accurate
processing compared to the samples needed for the determination of the input function.
Typically, 5-7 samples are taken and a model describing the intact fraction as function of
time is fitted through the data points to obtain the intact fraction for every time within the
measurement interval.
The most popular models used for this are:
1. The mono-exponential model given by
F(t) = Ae−
ln(2)
α t (2)
describing the fraction F(t) of intact tracer over time. The parameter A describes the
amplitude, while α describes the biological half live. Sometimes an additional constraint
A = 1 (i.e. at the time of the injection, we have 100% intact tracer) is imposed.
2. The bi-exponential model given by
F(t) = Ae−
ln(2)
α t + Be
− ln(2)β t (3)
in which A and B are the amplitudes of the two processes each described by a half-life α
respectively β. An additional constraint A + B = 1 with the same interpretation as above
can be imposed. An equivalent model is given by:
F(t) = Ae−
ln(2)
α (t−tdelay) + (1− A)e
− ln(2)β (t−tdelay) (4)
in which tdelay is a time-constant describing the delay before metabolisation takes place.
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(a) Intact fraction of tracer (b) Plasma input function
Fig. 1. Example of intact fraction and the plasma input function of [11C]-Flumazenil
3. A third model is the Hill model described by:
F(t) =
b
1+ ( at )
n
(5)
in which a, b and n are parameters that can be interpreted respectively as the time to
obtain half of the maximum value, the maximum value obtained at t = 0 if n < 0 (or
the asymptotic value at infinity if n > 0) and the steepness of the slope. If n < 0 and
b = 1, the Hill function starts at 1, then gradually decreases followed by a steep decrease
and ending with a gradual decrease towards 0.
An example of calculating the intact fraction of [11C]-Flumazenil is seen in figure 1 (left). The
blue line indicates a fit of the bi-exponential model (equation 3) with the constraint A + B = 1
while the black dots represent the individual measurement points. The optimization was
performed using multidimensional unconstrained nonlinear minimization (Nelder-Mead)
implemented in Matlab. The initial value for the fitting parameters are A = 0.5, α = 10
min and β = 100 min. The resulting fitted parameters are A = 0.75, α = 4.6 min and
β = 4.32 ∗ 1012 min. An example of a plasma input function is given in figure 1 (right). Black
dots represent the measurement of each sample (corrected for decay) and the blue line is the
input function after taking into account the intact fraction of tracer at each time point (using
the fitted function obtained in figure 1 (left).
Unfortunately, this fitting procedure is not described in many publications but can have a
major impact on the results. Furthermore, it is important to characterize the metabolites in
terms of their effect on the PET measurement in the tissue of interest. If the contribution of the
radioactive metabolite to the measured PET signal in the brain cannot be neglected, it should
be incorporated into the kinetic model.
Several groups have looked at alternatives to determine the arterial input function. A popular
approach is the so-called image-derived input function. Typically, a function which represents
the input function is derived from the dynamic images by determining the time-activity curve
in a small region including the carotid artery, positioned manually or (semi)automatically.
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Due to the limited spatial resolution of the PET image this function has to be corrected for
partial volume effects. Furthermore, activity in surrounding structures can affect this function
through spill-in effects.
One way of correcting for these effects is to take into account a recovery coefficient (ratio of
observed to true activity, estimated based on phantoms and computer simulations) and the
spill-in fraction from surrounding tissue (obtained from a nearby ROI) (Chen et al. (1998)).
Another option is to use a reconstruction algorithm with resolution recovery in combination
with a high-resolution PET (Mourik et al. (2008)). A possible alternative strategy that does
not use using any anatomical information, is to extract a time-activity curve by means of
an independent component analysis (ICA), which implicitly accounts for spill-over effects
(Naganawa et al. (2005)).
Depending on the method (e.g. the amplitude of the independent components is relative),
the extracted image-derived input function may need to be scaled using the concentration
determined in one or a few blood samples. Sometimes arterial samples can be replaced by
venous samples (Chen et al. (1998)), usually at later time points when venous and arterial
concentrations of tracer are almost equal. A more desirable alternative is to use so-called
blood free methods. For example, Croteau et al. (2010) fitted a tri-exponential function to the
extracted carotid time curve, using the carotid diameter as measured on MRI to correct for
the partial volume effect. In Backes et al. (2009), the measured time-activity curve Cm was
corrected as follows to obtain the image derived input function (Cinput−ID):
Cinput−ID(t) =
Cm(t)
av + (1− av)(1− e−kt)
(6)
in which av is the fraction of vessel in the ROI and k is the rate constant for the transport to
surrounding tissue. The main disadvantage of this method is that both parameters av and k
have to be estimated empirically.
Recently, in Zanotti-Fregonara et al. (2011) different approaches to determine the
image-derived input function were compared. The overall conclusion was threefold: 1)
image-derived input functions have to be carefully evaluated for a particular tracer and
setting, 2) blood samples are still necessary to obtain a reliable input function and 3)
techniques which use the integral of the input function (e.g. the Logan plot) give better results
compared to techniques in which the input function is used directly.
Another approach is to use a population based input function (usually in combination with
one or a few venous blood samples) (Hunter et al. (1996), Hapdey et al. (2011)). A population
based approach can also be used to correct an image derived input function for the intact
fraction of tracer.
Importantly, blood/plasma samples are measured in a well counter, dose is determined by
a dose calibrator and the activity in the brain is measured with PET. Each of these devices
has a different sensitivity and performance (optimal range of activity which can be measured
reliably). Since we need to combine the measurements in our modelling, the different
machines need to be cross-calibrated.
A summary of the main points to consider for the acquisition is given in table 1.
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Subject preparation
optimal positioning in scanner
head fixation and comfort of the subject
Tracer injection
constant infusion or bolus injection
effective dose injected
amount of injected ligand / specific activity
Transmission scan
PET based (68Ga/68Ge or 137Cs) or low-dose CT
Emission scan
list-mode or dynamic acquisition (frame definition)
scanning parameters (start and end time, time coincidence window, ...)
correction for decay, dead-time, scatter, randoms, ...
cross-calibration with dose calibrator and well counter
if possible: on-line motion correction
Other measurements
if input function needed
image derived
timing of blood samples
arterial or venous samples
if metabolite correction needed
timing of arterial samples
model to describe intact tracer fraction
EEG, ECG, blood pressure, ...
Table 1. Main points to consider for the acquisition.
3. Reconstruction
Each frame is reconstructed into a 3D image. There are two major classes of reconstruction:
filtered back projection and iterative reconstruction. Filtered back projection has the
advantage that it is fast and robust but the disadvantage that in low count measurements
streak artifacts occur in the reconstructed images. Iterative reconstruction techniques have
the advantage that a-priori information can be taken into account (e.g. the noise model, scatter
and attenuation measurements) avoiding precorrection of the raw data before reconstruction
which results in superior image quality. The disadvantage is that convergence is not uniform
throughout the imagemaking it sensitive to bias due to the limited number of iterations that is
often applied. Reconstruction time is alsomuch longer compared to filtered back projection. A
very popular and widely used method is OSEM (ordered subsets expectation maximization).
This method includes a Poisson-noise model and has a non-negativity constraint. The latter
can cause some bias in the parameters estimated when modelling the data. Several studies
(Boellaard et al. (2001), Oda et al. (2001), Belanger et al. (2004), Morimoto et al. (2006))
have compared iterative reconstruction methods with filtered back projection. The overall
conclusion was that both methods have a similar quantitative accuracy although in some
situations, filtered back projection may still be preferable. In a more recent study by Reilhac
et al. (2008), using simulations, it was shown that the positivity constraint in maximum
likelihood expectationmaximization (MLEM)-based algorithms leads to overestimation of the
activity in regions with low activity (e.g. in a reference region) which causes a significant bias
61inetic Modelling in Human Brain Imaging
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in binding potential estimates. However, the use of a resolution model reduces low-statistics
bias (Walker et al. (2011)).
Usually, the dynamic PET data are reconstructed frame by frame in an independent way
without taking into account the temporal relationship between subsequent frames. To
overcome this shortcoming, a 4D reconstruction has been developed in which all frames
are reconstructed simultaneously (for a recent overview, see Rahmim et al. (2009)). During
this 4D reconstruction, different techniques (e.g. iterative temporal smoothing, wavelet based
techniques to control noise) can be used to handle temporal information. A particularly
interesting approach is to model the data directly from the sinograms. This was first described
by Maguire et al. (1996) and is now more widely studied in the context of 4D reconstruction.
Because it is rather difficult to model the noise distribution in reconstructed images, the
spatially variant noise distribution is neglected when doing kinetic modelling. By calculating
sinograms of the physiological parameters directly from the raw data this problem can be
circumvented. These sinograms are subsequently reconstructed to form parametric images.
The best results with this approach so far have been obtained when using a Gjedde-Patlak
model as shown by Wang et al. (2008), and Wang and Qi (2009), but other models are also
possible.
Another new development is the use of anatomical knowledge that is available from other
imaging modalities (like MRI). One such a technique is the anatomically based maximum a
posteriori reconstruction (A-MAP) (Baete et al. (2005)), which corrects the images for partial
volume effects, the importance of which is described in the next section.
A summary of the main points to consider for the reconstruction is given in table 2.
Definition of frames (rebinning from list mode)
Pre-corrections if necessary (e.g. random correction)
Reconstruction method: iterative reconstruction or filtered back-projection
reconstruction time
inclusion of additional measurements (scatter, attenuation, . . .)
filtering
effect of reconstruction on final results (bias, variance, resolution)
Optionally, take into account:
temporal relation between frames (4D reconstructions)
anatomical knowledge (partial volume correction)
Data management
Quality assurance of reconstructed images
Table 2. Main points to consider for the reconstruction
4. Processing
Since dynamic PETmeasurements are long, patientmovement is almost inevitable andmotion
correction should be applied. Implicit in the previous step of reconstruction is that either the
transmission scan or the CT scan are in (near) perfect spatial alignment with the PET frames
to be attenuation corrected. Also, the different PET frames themselves should be spatially
aligned since the next step of kinetic modelling assumes that the time course (in voxels or
areas) is derived from the same location.
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Motion correction poses two particular difficulties: the first frames are too noisy to use and
any movement occurring during a frame is neglected. The first issue can be solved by creating
a sum image of the first fewminutes reasonably assuming that there was no significant motion
during this period and by coregistering all subsequent frames to this sum image. The second
issue is more problematic, but as long as movements are small (i.e. less than a few mm in
displacement or a few degrees in rotation) this leads to limited additional blurring of the
image and will not cause a major problem.
Realigning PET frames to the first frame or a sum image can be done by simply minimising
the intensity differences between the images, but in some cases it may be necessary to use
more complex measures of similarity between the images based on more general information
than simple intensity, such as mutual information or cross correlation. Examples of such
situations are when tracer uptake patterns differ drastically over time or when one needs
to coregister another imaging modality (e.g. a CT or MRI image) to a PET frame. When
realigning within an imaging modality (e.g. PET frames) rigid (6 parameters: 3 translational
and 3 rotational parameters) spatial transformations are usually sufficient. Coregistrations
between different modalities benefit from affine (12 parameter) transformations allowing
additionally 3 directions of zoom and of skew although a rigid body transformation is often
acceptable.
Having a high resolution structural scan, usually a T1-weighted MRI, of the same subject
coregistered to the PET scan may serve multiple purposes. First, the MRI can be used to draw
anatomical volumes of interest (VOIs) for subsequent kinetic modelling with much higher
precision than is possible based on PET scans and, importantly, unbiased from the pattern of
tracer uptake. Second, the structural scan can be used to calculate a potentially more precise
(due to higher resolution of the source image) spatial transformation that takes the subject’s
brain into a common stereotactic space, such as Montreal Neurological Institute (MNI) space.
This allows direct comparisons across subjects in this standard space. Alternatively, the
obtained spatial transformation can be inverted and applied to MNI space VOI templates
to bring them into the subject’s native space if one prefers to avoid interpolation issues and
working on distorted images. Third, the structural scan provides high resolution anatomical
information needed to perform partial volume correction.
The partial volume effect (PVE) stems from the relatively low spatial resolution of the PET
scanner. This can be quantified by means of the system’s point spread function (PSF),
which describes the degree to which a point source is ’blurred’ by the imaging system.
More specifically, when imaging a radioactive point source (perfect impulse function), this
object appears larger but less intense (bell shaped curve), since the total number of counts is
preserved. Applied to brain imaging, this means that for structures that are smaller than the
sampling resolution (about 4 mm FWHM for modern scanners), e.g. the cortex, the measured
signal is a mix of the true radiotracer concentrations in the multiple tissue types present. As
such, the measured activity in grey matter is affected by spill-out onto other tissues (e.g. CSF)
and spill-in from adjacent white matter.
This effect poses a particular problem when one wishes to study decreases in tracer binding
in patients. A lower measured signal could mean a true decrease in tracer binding, PVE due
to tissue atrophy or a mixture of both. In order to disentangle these effects, a formal partial
volume correction (PVC) can be applied, based on prior higher resolution knowledge about
the underlying tissue types and the point spread function of the scanner.
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The basic idea is to view the measured PET signal as a convolution of the true image by the
PSF and correct the measured PET signal in a voxel/region by modelling it as a combination
of effects in the various tissue types present, taking into account the proportion of those tissue
classes in that voxel/region.
The prior anatomical knowledge is derived from a high resolution structural scan, nowadays
usually an MRI scan, which is segmented into the tissue types of interest, commonly taken
to be grey matter, white matter and cerebrospinal fluid (CSF). The image values in such
segmentation maps (e.g. a voxel with a value of 0.8 in a grey matter map) can be interpreted as
the tissue fraction (80% of the voxel consists of greymatter) or probability (80% chance that the
voxel belongs to grey matter). Importantly, the quality and accuracy of these segmentations
will propagate into the partial volume corrected PET images. .
Here, for illustrative purposes, we describe a commonly used method, the Müller-Gärtner
partial volume correction (Müller-Gärtner et al. (1992)), to correct the activity in grey matter
tissue.
IGM =
Imeasured − (IWMPWM)⊗ PSF − (ICSFPCSF)⊗ PSF
PGM ⊗ PSF
(7)
where IGM is the partial volume corrected image, Imeasured the original PET image, IWM and
ICSF the tracer uptake in white matter and CSF, PGM, PWM and PCSF the tissue probabilities,
and PSF the system’s point spread function.
The corrected image value IGM is obtained by subtracting from the measured value Imeasured
the contributions of white matter and CSF signal. These contributions are given by the tissue’s
tracer uptake e.g. IWM weighted by the proportion PWM of that particular tissue class in
the voxel/area and convolved with the PET system’s PSF to match the resolution of the
higher-resolution tissue probability maps with the PET image. In order to obtain ’pure’ grey
matter tracer uptake (i.e. independent of how much grey matter is present in the voxel/area),
the result is divided by the proportion of grey matter PGM, again convolved with the PSF.
The PSF of a PET system can be measured and varies spatially, being the most narrow at the
centre of the scanner. For brain scans, this spatial variability is thought to be negligible. PGM,
PWM and PCSF are derived from the tissue probability maps. Under the assumption that tracer
uptake is homogeneous throughout white matter, a representative uptake value for IWM can
be obtained bymeasuring the PET signal within a ’pure’WM area where there is no significant
spill-in from other tissues, such as the centrum semiovale. Likewise ICSF can be derived from
a pure CSF region or can be assumed to be zero since CSF should not show any tracer uptake.
While the Müller-Gärtner PVC is a postprocessing method performed after image
reconstruction, a similar strategy can be applied during iterative reconstruction incorporating
anatomical information as a priori knowledge, such as A-MAP (Baete et al. (2005)). The
latter approach offers a better spatial resolution, since smoothing (which is done during
reconstruction in order to suppress noise) can be restricted to a specific tissue class instead
of increasing spill-over between tissue classes, yielding sharper anatomical boundaries.
PVC can be applied on a voxel- or VOI-based level, the advantages and disadvantages of
which are discussed inmore depth later. Errors in registration of tissuemaps to the PET image,
misclassifications in the tissue probability maps, and VOI misplacement may all introduce
errors that propagate in further analyses on partial volume corrected data.
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Theoretically, PVC would preferably be applied prior to kinetic modelling, since there is
usually not a simple linear relationship between raw counts and kinetic modelling output
measures that are eventually used to describe processes of interest.
Images can be smoothed prior to kinetic modelling (parametric imaging), or are smoothed
implicitly by using the VOI approach. Eithermethodwill attempt to find the kinetic modelling
coefficient that best describe the data, either in each voxel or in each VOI independently of the
other voxels/VOIs.
A summary of the main points to consider for the processing is given in table 3.
Motion correction
sum the first frames (e.g. first 5 minutes assuming no movement)
align all images of the remaining frames
method
evaluation of motion parameters
Coregistration with high-resolution anatomical MRI
method (transformation, cost-function)
PET image (e.g. summed image of all frames)
Use high-resolution anatomical MRI
to draw volumes of interest
to correct for partial volume effects
to determine the spatial transformation to a common anatomical space
Smoothing of PET data (noise reduction)
Table 3. Main points to consider for image processing
5. Kinetic models
5.1 Pharmacological terminology
When describing the pharmacokinetics of a tracer, the most commonly used method is a
compartmental model (figure 2), where distinct pools of tracer (spatial location or chemical
state) are assigned to different compartments. It is assumed that the tracer concentration
in a compartment, given by C (e.g. expressed in Bq ml−1), is homogeneous (instantaneous
mixing assumption). The rate of exchange of tracer between 2 compartments is given by a
rate constant k (in fraction per time, e.g. min−1).
The rate at which the tracer crosses the blood-brain barrier (BBB) to enter the first brain
compartment is given by K1, the only rate constant historically denoted in upper case and
having units of ml plasma per cubic cm tissue per min (ml cm−3 min−1). This rate constant
for blood-brain barrier transport is related to perfusion (blood flow).
In a capillary model, the following relation can be derived
K1 = EF (8)
where E is the unidirectional extraction from blood into brain during the tracer’s first pass
through the capillary bed, and F denotes the blood flow. Regarding the capillary as a rigid
tube, the Renkin-Crone model posits that
E = 1− e−
PS
F (9)
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Fig. 2. One-tissue compartement model
with PS the permeability surface product (the tracer’s total permeability across the capillary
membrane).
On one end of the spectrum, for tracers with a large permeability surface product (freely
diffusible tracers e.g. water), extraction is virtually independent of perfusion and approaches
1 (the exponential term is very small). As a result, K1 approximates blood flow for such tracers.
On the other end, for tracers with a permeability surface product much lower than the blood
flow, E can be approximated by PS/F and hence K1 is no longer related to blood flow but is
proportional tot the permeability surface product (K1 ≈ PS).
Two interacting compartments commonly found in a model are ligand and receptor. A
ligand is a chemical that binds to a receptor. If this binding results in a chemical response
i.e. ’activates’ the receptor, the ligand is called an agonist. More specifically, the term
’agonist’ is used for molecules that induce a pharmacological response mimicking the action
of the naturally occurring compound, e.g. the binding of morphine to opioid receptors
mimics the action of the endogenous endorphins. An ’inverse agonist’ induces the opposite
pharmacological response as the agonist. Finally, a ligand is called an antagonist if its binding
does not activate the receptor or appears to ’deactivate’ it by displacing an agonist.
Receptor occupancy refers to the percentage of receptors that are currently being occupied
by ligands. The aim of PET receptor displacement studies is to detect changes in receptor
occupancy caused by the experimental action of introducing a nonradioactive ligand. By
measuring the difference in binding of the radioactive tracer, which is applied before and after
the pharmacological challenge, the occupancy of the nonradioactive ligand can be inferred.
For example, if the non-radioactive compound occupies 25% of binding sites, relative tracer
bindingwill decrease by around 25% as well. This is explained inmore detail in a later section.
In vitro, ligand-receptor kinetics is described by the well-known Michaelis-Menten
relationship for a reversible binding.
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L + R
kon
−⇀↽−
koff
LR
(10)
where L = ligand, R = receptor, LR = ligand-receptor complex, kon = rate constant of association
and ko f f = rate constant of dissociation. According to the law of mass action, the kinetics of
this system are described by
dCLR
dt
(t) = konCL(t)CR(t)− ko f f CLR(t) (11)
with CL, CR and CLR being the concentration of respectively L, R and LR.
When the system reaches a dynamic equilibrium:
konCLCR = ko f f CLR (12)
Rearranging the previous equation gives the definition of the dissociation constant, KD:
KD =
ko f f
kon
=
CLCR
CLR
(13)
The affinity of a receptor for the ligand is defined as 1/KD.
Furthermore, the total concentration of receptors, free and bound, or receptor density is
Bmax = CLR + CR (14)
Here we have assumed that none of the receptors are bound by endogenous ligands.
Rearranging the two previous equations gives
CLR =
BmaxCL
KD + CL
(15)
This relationship is termed a saturation binding curve. Bmax is the asymptotic value
representing the occupation of all available receptors. KD is the concentration of ligand at
which 50% of all receptors have been saturated (if CL = KD, then CLR = 0.5Bmax). The initial
slope of the saturation curve is Bmax/KD.
The in vitro binding potential is defined as
BP = lim
CL→0
CLR
CL
(16)
Since PET studies employ tracer doses (i.e. occupying a negligible percentage of receptors,
often taken to be 5%), the concentration of free ligand is very small compared to KD and
hence may be ignored. Using equation 15, BP can be written as:
BP =
Bmax
Kd
(17)
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It is usually assumed that changes in BP aremainly due to changes in total number of receptors
(Bmax) while affinity (=1/KD) of the tracer for the receptor is similar. While in vitro ligand
binding consists of a single compartment, in vivo PETmodels include plasma and one or more
tissue compartments, thus requiring a slightly different definition of BP, as will described in
more detail later.
A related concept to BP is the volume of distribution (or distribution volume). Similar to BP,
there are also slightly different in vivo definitions of the volume of distribution, which will be
discussed later. In its original pharmacological definition, the apparent volume of distribution
is the virtual plasma volume that the drug would have to occupy in order to adopt the same
(uniformly distributed) concentration in the body as in the blood plasma. Put differently, it
is the ratio of the total drug amount in the body (administered dose) over the drug’s plasma
concentration (at equilibrium). For example, if 5 mg of a drug is present in the body, and its
plasma concentration is 250 ng per ml, then a virtual volume of 20 l plasma would be needed
to contain 5 mg of the drug.
In PET, the volume of distribution VT is based on a similar conceptual idea but has been
adapted slightly: it relates to a specific organ of interest instead of the entire body and uses
the tracer’s concentration (amount per volume) instead of volume (Innis et al. (2007)).
VT =
CT
Ca
(18)
where CT is the tracer’s concentration in the tissue and Ca is the tracer’s arterial plasma
concentration, assuming equilibrium has been reached. Hence, its values are expressed in ml
per cm3 which is in fact unitless since 1 ml = 1 cm3. For example, if the tracer’s concentration
is 50 kBq cm−3 in the brain and 2.5 kBq ml−1 in plasma, then VT is 20, or, in other words:
in order to have the same amount of tracer as in 1 cm3 of brain, 20 ml of plasma would be
needed.
In contrast to the in vitro definition of binding potential, the in vivo situation is much more
complex. A fraction fp of tracer is bound to plasma proteins and will not pass the blood
brain barrier. Usually, a reliable estimate of this fraction is difficult. Another fraction of intact
tracer is protein bound in the brain (non-specific binding representing the non-displaceable
compartment). The free fraction of tracer available for binding to the receptor is denoted
fND according to the consensus nomenclature (Innis et al. (2007)). Therefore, three different
definitions of binding potential in PET exist which can be expressed as a ratio at equilibrium:
1. BPF: the ratio of the concentration of specifically bound tracer to the concentration of
free tracer in tissue. We assume that the concentration of free tracer in tissue equals the
concentration of free tracer in plasma.
2. BPP: the ratio of the concentration of specifically bound tracer in tissue to the concentration
of intact tracer in plasma (both free and protein bound).
3. BPND: the ratio of the concentration of specifically bound tracer in tissue to the
concentration of non-displaceable tracer in tissue.
There is a linear relation between these three values: BPND = fNDBF and BPP = fpBF.
Analogous to the different definitions of binding potential, different definitions exist for the
volume of distribution. The total tracer concentration CT in tissue can be written as the sum
of three different parts:
CT = CLR + CNS + CL (19)
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in which CLR is the concentration of tracer bound to the receptor, CNS is the concentration of
nonspecific bound tracer and CL is the concentration of free available tracer. The concentration
of the non-displaceable part is given by CND = CL + CNS. Besides VT , the volume of
distribution of all radioligand, we also define the distribution volume of the non-displaceable
part of the tracer as:
VND = CND/Ca. (20)
Note that in an in vivo setting, Bmax should actually be replaced by B
′ which is the
maximum concentration of available receptors, i.e. not occupied by endogenous ligands or
compartmentized in a low affinity state.
The binding potential that we measure with PET is BPND and the relation with the volume of
distribution is:
BPND =
VT −VND
VND
=
VT
VND
− 1 = DVR− 1 (21)
with DVR the volume of distribution ratio.
BP and VT are combinations of the rate constants introduced in the compartmental models as
will be shown in a later section.
A common assumption in compartmental modelling is that the underlying physiological
processes are not influenced by the presence of the tracer and are in a steady-state, i.e. the rate
constants do not change over time. In this case, linear differential equations can be used to
describe how changes in concentration in one compartment influence concentration in another
one. The tissue compartments can refer to physical locations (e.g. outside vs. inside the cell)
or chemical states (e.g. free vs. bound ligand).
The general aim is to estimate one or more of the rate constants, either individually or in
some combination such as BP and VT . The parameter estimation is based on the measured
PET signal in the brain and the concentration in arterial blood measured by the arterial input
function.
5.2 Model simplification
Accurate models describing the full behaviour of a tracer are too complex to be used
in practice. Therefore, model simplifications are used. We show here the example of
the well-known tracer [18F]-FDG used when measuring the metabolic rate of glucose
consumption. In figure 3, a model for the PET tracer [18F]-FDG, consisting of both physical
spaces (vascular, interstitial and cellular) and chemical compartments (FDG and FDG-6-PO4)
is shown. Constants K1, k2, k5 and k6 describe the rate of transport of FDG between
the physical compartments, while rate constants k3 and k4 give the phosphorylation and
dephosphorylation rates respectively. The blood-brain-barrier is indicated by BBB.
The transport of glucose or FDG across the cell membrane in cerebral tissue is very fast
as compared with the transport across the capillary wall and the phosphorylation reaction
catalyzed by hexokinase. The concentration ratio between the interstitial space and the
cellular space is nearly in equilibrium at all times. Therefore, the interstitial and the cellular
space can be approximated as a single compartment. This leads to the well-known two-tissue
compartment of [18F]-FDG (figure 4). In addition in the brain almost no dephosphorylation of
FDG-6-PO4 takes place within the first hour which leads to a further simplification in which
k4 = 0.
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Fig. 3. Extended FDG model
Fig. 4. simplified FDG model
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FDG and glucose behave differently because FDG becomes trapped after phosphorylation.
Influx/uptake of FDG is only proportional to the influx/uptake of glucose. The constant of
proportionality is called the lumped constant LC.
5.3 Compartmental models
5.3.1 One-tissue compartment model
In the one-tissue compartment model, we have two rate constants K1 and k2 describing the
model (see figure 2). The differential equation is given by:
dCT
dt
(t) = K1Ca(t)− k2CT(t), (22)
where Ca is the arterial plasma concentration of intact tracer and CT is the concentration of
tracer in tissue. This model is also called the Kety-Schmidt model originally developed to
model tracers measuring regional cerebral blood flow.
The solution of this equation is given by:
CT(t) = K1
∫ t
0
e−k2(t−s)Ca(s)ds = K1e
−k2t ⊗ Ca (23)
Using this expression, the rate constants can be estimated based upon the measurement of Ca
and CT at different time points. This estimation is a nonlinear operation.
A linear alternative can be formulated by integrating both sides of the differential equation
22:
CT(t)− CT(0) = K1
∫ t
0
Ca(s)ds− k2
∫ t
0
CT(s)ds. (24)
Assuming CT(0) = 0, we find the following linear relation:
CT(t)∫ t
0 Ca(s)ds
= K1 − k2
∫ t
0 CT(s)ds∫ t
0 Ca(s)ds
. (25)
From this equation, K1 and k2 can be estimated using linear regression. The distribution
volume can then be calculated as:
VT =
K1
k2
. (26)
5.3.2 Two-tissue reversible compartment model
In the two-tissue compartment model, K1 and k2 again describe the exchange of tracer with
the blood pool similar as in the one-tissue compartment model. Two additional rate constants,
k3 and k4, model the interactions between the 2 tissue compartments.
Tracer behaviour in this model (5) is described by the following set of differential equations:
CT(t) =
dC f+ns
dt
(t) = K1Ca(t)− (k2 + k3)C f+ns(t) + k4Cb(t)
dCb
dt
(t) = k3C f+ns(t)− k4Cb(t)
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Fig. 5. Two-tissue reversible compartment model
where C f+ns denotes the concentration of free and non-specifically bound tracer and Cb is the
concentration of specifically bound tracer. Reworking these equations gives
C f+ns(t) + Cb(t) = (φ1e
−θ1t + φ2e
−θ2t)⊗ Ca(t) (27)
φ1 =
K1(θ1 − k3 − k4)
∆
φ2 =
K1(θ2 − k3 − k4)
−∆
θ1 =
k2 + k3 + k4 + ∆
2
(28)
θ2 =
k2 + k3 + k4 − ∆
2
(29)
∆ =
√
(k2 + k3 + k4)2 − 4k2k4 (30)
The distribution volume is given by:
VT =
K1
k2
(1+
k3
k4
) (31)
An example of a time-activity curve in a right frontal region in a normal subject injected with
[11C]-FMZ and the corresponding fit obtained using the two-tissue compartment model, is
given in figure 6. The initial values for the rate constants were: K1 = 0.300 ml cm
−3 min−1;
k2 = 0.100 min
−1; k3 = 0.050 min
−1; k4 = 0.030 min
−1 and the fitted values were K1 = 0.302
ml cm−3 min−1; k2 = 0.076 min
−1; k3 = 0.010 min
−1 ; k4 = 0.041 min
−1. We also fitted the
fraction of blood in the VOI (see below): the initial value was Vb = 0.05 and the fitted value
was Vb = 0.08.
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Fig. 6. Measured time activity curve (dots) and the corresponding fit (full line) using a
two-tissue compartment model
5.3.3 Two-tissue irreversible compartment model
In case of irreversible binding, e.g. FDG, k4 can be assumed to be 0 and the compartmental
model equations simplify to:
dC f+ns
dt
(t) = K1Ca(t)− (k2 + k3)C f+ns(t)
dCb
dt
(t) = k3C f (t)
CT(t) = C f+ns(t) + Cb(t) = {
K1k2
k2 + k3
e−(k2+k3)t +
K1k3
k2 + k3
} ⊗ Ca(t) (32)
KI =
K1k3
k2+ k3
(33)
KI is the net influx constant, the overall net rate of tracer uptake into tissue.
5.4 Graphical models
5.4.1 Gjedde-Patlak approach
This is an example of a graphical method which is derived using the assumption that k4 = 0
(irreversible tracer) and that there is a steady state between the tissue concentration in the
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reversible compartment and the blood or plasma concentration. Under these conditions we
find:
CT(t)
Ca(t)
= KI
∫ t
0 Ca(s)ds
Ca(t)
−
K1k2
(k2 + k3)2
(34)
with CT being the tissue concentration, Ca the arterial blood or plasma concentration, KI is
given by equation (33) and K1, k2 and k3 the time independent rate-constants. Equation (34)
is an asymptotic relation but in practice the steady state is reached within 20-30 minutes for
tracers like [18F]-FDG. The time after which we assume steady state is denoted by t∗.
5.4.2 Logan approach
For tracers with reversible binding kinetics, the following linear regression can be performed,
assuming the relationship becomes linear (steady-state) after t = t∗:
∫ t
0 CT(s)ds
CT(t)
= A + VT
∫ t
0 Ca(s)ds
CT(t)
(35)
The slope VT is the distribution volume given by equation (31) and the intercept is given by
A = − k2k4k2+k3+k4 .
Figure 7 shows an example of a time-activity curve of [11C]flumazenil (FMZ) transformed
according to the above formula in which X =
∫ t
0
Ca(s)ds
CT(t)
and Y =
∫ t
0
CT(s)ds
CT(t)
. The estimated
value for VT = 4.89 and t
∗ was chosen as t∗ = 20min.
5.5 Reference models
5.5.1 Reference Tissue Model (RTM)
Sometimes, the arterial input function can be replaced by a reference region providing an
indirect input function. More specifically, in this reference region there should be no specific
tracer binding, hence making it possible to estimate the contribution of non-specific tracer
binding to the signal in the tissue of interest (Lammertsma et al. (1996)).
Figure 8 depicts a reference tissue model, described by the following differential equations:
dCr
dt
(t) = K′1Ca(t)− k
′
2Cr(t)
dC f+ns
dt
(t) = K1Ca(t)− (k2 + k3)C f+ns(t) + k4Cb(t)
dCb
dt
(t) = k3C f+ns(t)− k4Cb(t)
where Cr is the nonspecific tracer concentration (and themeasured PET signal) in the reference
region, and K′1 and k
′
2 are the rate constant describing resp. tracer influx into and outflow from
the reference tissue. The two lower equations are those of the standard 2-tissue compartment
model described higher, with CT(t) = C f+ns(t) + Cb(t).
It is assumed that the volume of distribution of the non-specifically bound tracer is similar
in both the tissue of interest and the reference region, i.e. K1/k2 = K
′
1/k
′
2. Hence, CT can be
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Fig. 7. Logan plot
Fig. 8. Reference tissue model
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described as a function of Cr omitting the need for the arterial input function Ca. The solution
is given by:
CT(t) = R1[Cr(t) + A1e
−θ1t + A2E
−θ2t]⊗ Cr (36)
with
A1 =
θ1 − k3 − k4
∆
(
k2
R1
− θ1)
A2 =
k3 + k4 − θ2
∆
(
k2
R1
− θ2)
R1 =
K1
K′1
(37)
and the parameters θ1, θ2 and ∆ are given by equations (28-30). The parameters R1, k2, k3 and
k4 have to be estimated.
5.5.2 Simplified Reference Tissue Model (SRTM)
The reference tissue model can be further simplified if it can be assumed that the free and
bound compartments of the tissue of interest are not readily distinguishable, i.e. can be
described by one compartment. This reduces the number of parameters to be estimated from
four to three, reducing standard errors on the estimates and speeding up convergence. The
solution in this case is given by (Lammertsma & Hume (1996)):
CT(t) = R1Cr(t) + k2(1−
R1
1+ BPND
)Cr ⊗ e
−
k2 t
1+BPND (38)
with R1 given by equation (37). The parameters R1, k2, and BND have to be estimated.
5.5.3 Reference logan
The Logan approach described above can also be applied when using a reference region
instead of the arterial input function. In that case the operational equation becomes (Logan et
al. (1996)): ∫ t
0 CT(τ)dτ
CT(t)
= DVR
∫ t
0 Cr(τ)dτ
CT(t)
+ B (39)
in which DVR = BND + 1 and B is assumed to be constant (when CT/Cr is constant after
some time t*).
5.5.4 Multilinear reference tissue model (MRTM)
In the reference Logan model, it is assumed that CT/Cr becomes constant after some time. If
this is not the case, the Ichise model MRTM0 can be used (Ichise et al. (2003)):
∫ t
0 CT(τ)dτ
CT(t)
= DVR
∫ t
0 Cr(τ)dτ
CT(t)
+ A′
Cr(t)
CT(t)
+ b (40)
in which DVR = BND + 1, A
′ = −DVR/k′2 and b is assumed to be constant.
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This equation can be rearranged in the following form (MRTM):
CT(t) = −
DVR
b
∫ t
0
Cr(s)ds +
1
b
∫ t
0
CT(s)ds−
DVR
k′2b
Cr(t). (41)
The advantage of this expression is that CT is not present in the independent variables because
CT can be noisy.
Other variants of these models exist in which k′2 is assumed to be known. The difference
between these models is mainly based on the strategy to determine k′2.
5.6 Displacement studies
Displacement studies are important in the validation process of a new tracer. Based on in vitro
experiments, the affinity for a receptor system can be determined but this doesn’t guarantee
that the tracer will behave in vivo exactly as predicted. By performing an in vivo displacement
study, the binding to a certain receptor system can be proven. The underlying assumption is
that the drug used for the displacement study has a well-characterized affinity for the receptor
system under investigation which is higher than the affinity of the tracer itself. If this is not
the case, the displacement will be more subtle and may not be detectable.
A displacement study starts with the injected tracer (either as bolus or constant infusion)
having reached an equilibrium state. This is disturbed by introducing a nonradioactive
competitor which can be either endogenous (e.g. subject performs a cognitive task resulting
in neurotransmitter release) or exogenous (e.g. infusion of a drug). The nonradioactive
ligand ‘displaces’ the radioactive one by occupying available receptors hence promoting tracer
wash-out (assuming the tracer is not bound irreversibly). The decrease in tracer binding can be
detected either by comparing two scans, one with and onewithout nonradioactive competitor,
or by modelling the competition (e.g. Morris and Yoder (2007)).
5.7 Occupancy studies
Occupancy studies are important to test new drugs. Too little occupancy of specific target
receptors will not lead to a drug effect while a dose that is much higher than needed to
occupy almost all receptors of the target, will not show additional benefits and may cause
more negative side-effects than necessary.
Occupancy O of a target receptor system by a drug is defined as:
O(t) = 100.
VT(0)−VT(t)
VT(0)−VND
(42)
in which VT(0) is the volume of distribution at baseline (i.e. no drug is given), VT(t) is the
volume of distribution at time t after drug intake and VND is the volume of distribution of
the non-displaceable part of the tracer, i.e. the free and non-specifically bound tracer (e.g. as
measured in a reference region where the target receptor is absent). Note that the occupancy
is expressed in % and that it is time-dependent. It can also vary across different parts of the
brain.
Unlike displacement studies, occupancy studies start with a certain equilibrium level of
cold ligand (the drug of interest) present, followed by injection of the tracer to estimate the
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remaining fraction of available receptors not bound by the drug. In addition to one baseline
scan in the absence of the drug, this typically requires multiple scans at different time points.
These time points depend on the kinetics of the drug under investigation. The number of time
points is limited by constraints on the amount of blood that can be sampled (if applicable)
and on the radiation exposure to the subject. Therefore, occupancy studies are often first
performed in monkeys in which at least the constraint on the radiation exposure is weaker
compared to humans. In such a case, the occupancy is expressed as function of the plasma
concentration of the drug and this relationship is usually modelled with a Hill function. Based
on these animal data and on plasma kinetics data in humans, a few time points can be selected
to determine the occupancy in-vivo in humans.
5.8 Optimization procedures
The model estimate yˆi of the PET measurement yi of frame i is given by:
yˆi =
∫ tei
tbi
{(1−Vb)CT(s) + VbCa(s)}ds
tei − t
b
i
(43)
in which tbi and t
e
i are the begin time respectively end time of frame i. Vb is the fraction of
blood in the volume of interest which can be fitted or fixed to some value. If we have an
appropriate sampling scheme, we can approximate Mi by
yˆi = (1−Vb)CT(ti) + VbCa(ti) (44)
where the midscan time of frame i is given by ti = (t
e
i − t
b
i )/2.
The cost function O that is used very often, is then defined as:
O =
N
∑
i=1
wi(yi − yˆi)
2 (45)
in which N is the number of frames, wi is the weigth of frame i, and yˆi is the model estimate
of observation yi. The weight is typically inversely proportional to the variance σ
2
i in frame i:
wi =
1
σ2i
. (46)
Several models for the variance can be used: e.g. a uniform variance model, a model taking
into account the decay correction factors or a model based on the length of the frame, the
number of trues and the decay factor that is used. Each of these models will introduce some
bias compared to the true variance which is very difficult to determine (Yaqub et al. (2006)).
Weights are normalized so that they sum to 1. A priori it is not easy to determine which
weighting scheme is the most appropriate but often a uniform weighting scheme is used.
In some models (e.g. reference Logan), we assume that yˆi = CT(ti).
Every model contains one or more parameters which have to be estimated. In some cases
parameters can be calculated based on a linear regression but often it is necessary to use
non-linear estimation methods. Furthermore, many parameters of interest are by definition
positive and it can be useful to constrain the solution to a physiologically acceptable range.
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Amajor problem when using non-linear estimation methods, is that they are time consuming
and depend on the initial values that have to be set. In a high-dimensional space (in
which each dimension represents a parameter that has to be fitted) with noisy data, the cost
function has many local minima. Depending on the initial condition and on the mathematical
algorithm that is used, the result of the optimization problem is a local minimum that
unfortunately need not to be the global minimum. If we use global optimization algorithms
like simulated annealing, we will in theory find the global minimum but the time to find the
solution is much longer compared to the other optimization algorithms.
In addition to the presence of local minima, other factors affecting the accuracy of the solution
are the initial values if needed, the noise in the data, and the correlation that may be present
among different variables.
A summary of the main points to consider for kinetic modelling is given in table 4.
Models
compartmental models
number of compartments
interpretation of compartments
reversible or irreversible binding
parameters of interest
graphical models (linearization)
choice of model
assumptions
if needed, start time for linearization (t∗)
reference models
compartmental or graphical model
choice of reference region
assumptions regarding reference region tracer kinetics
Displacement studies
assumptions about competitor drug’s kinetics and affinity
compare 2 scans or model competition
Occupancy studies
assumptions about inital cold ligand’s kinetics and affinity
selected time points for scans (e.g. based on animal studies)
Optimization
cost function
initial values
constrain solution to physiologically acceptable range
mathematical algorithm for optimization
Volume of interest or voxel-based approach
size of the smoothing kernel reflecting expected effect size (voxel-based)
processing time
VOI definition
error estimates (voxel-based)
Table 4. Main points to consider for kinetic modelling
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6. Model selection
When comparing models or when looking for the best model, the problem of a gold standard
arises. Often, a two-tissue compartment model with a measured input function is considered
the ”best” model. Although this might theoretically be one of the best models, in practice
this model is sensitive to all kinds of errors (movement of the patient, errors in timing, errors
in determining the input function, etc). This is of course true for other methods as well but
simplified models tend to be more robust. One way to solve this, is to use more realistic
simulations to study the sensitivity of models to this type of error. Furthermore, when real
measurements are used, a strict quality assurance protocol should be in place to evaluate the
quality of all data and to minimize errors.
Despite this, comparing different models is complex. Models with more parameters tend to
more accurately describe the data. Let P be the number of parameters in the model, N the
number of observations and SS the residual sum of squares given by:
SS =
N
∑
i=1
wi(yi − yˆi)
2 (47)
in which wi is the weight of observation i, yi is the i-th observation and yˆi is themodel estimate
of observation i.
Several measures exist to help in model selection, the two most popular ones being the Akaiki
and the Schwarz criteria:
1. The Akaike information criterion AIC is defined as in Turkheimer et al. (2003):
AIC = N ln(
SS
N
) + 2P. (48)
Usually, N is not large enough compared to P (i.e. NP < 40) and in such a case we have to
use an expression with a correction term (Turkheimer et al. (2003)):
AICcor = N ln(
SS
N
) + 2P +
2P(P + 1)
N − P− 1
. (49)
2. Another criterion that is used sometimes, is the Schwarz criterion given by:
SC = N ln(
SS
N
) + P ln(N). (50)
In both cases, the model with the lowest value is the most appropriate.
To study the agreement between two different models (or a model and the gold standard),
a Bland-Altman plot can be used. This is a plot in which the difference between two model
parameters is plotted as function of the average value. It offers a better way of assessing
the agreement between two different methods than plotting a correlation between the two
different methods since a correlation can simply be high when there is a lot of variability
within each method.
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Fig. 9. Parametric image of DVR when using the tracer [11C]-Carfentanil to measure opioid
receptors
7. Parametric imaging
In traditional parametric image analysis, a kinetic model is performed in each (brain) voxel
independently. In contrast, VOI based analysis is spatially biased due to the observer drawing
VOIs or at least selecting usually anatomical areas to include in each VOI. Since there is no
averaging of the signal over multiple voxels (and potentially large areas), voxel-based analysis
is more sensitive than VOI based approaches to pick up small localised changes, but also to
noise that will propagate throughout the analysis. As a trade-off, some spatial sensitivity is
sacrificed to reduce the effect of noise in the input data (frames of raw counts) by smoothing
the data prior to kinetic modelling, e.g. with a Gaussian kernel with a small full width at half
maximum (FWHM) such as 6 mm.
Partial volume correction can be performed in a voxel-wise manner as well, by segmenting
a coregistered anatomical MRI image into grey matter, white matter and cerebrospinal
fluid. The effects of misregistrations and inaccurate segmentations are more likely to impact
voxel-wise analyses whereas they may average out in VOI-based analyses.
The resulting output will be parametric images of the kinetic modelling parameters, such
as k3 or DVR (figure 9), which can then be entered into voxel-wise statistical analyses after
being spatially warped into a common stereotactic (e.g. MNI) space and another smoothing
operation is performed. This pre-analysis smoothing serves to correct for remaining
inaccuracies in spatial normalisation and normal intersubject variability, but also to ensure
assumptions are met for voxel-wise parametric statistics (more specifically, its correction for
multiple comparisons by means of Gaussian random field theory). In general, the size of the
smoothing kernel determines the size of the effects the analysis is most sensitive to. Smoothing
kernels around 10 mm FWHM are commonly used.
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8. Future developments
A great challenge is to apply kinetic modelling in small animal brain imaging. Small animal
imaging using dedicated PET systems has its own problems and limitations and although
theoretically most of what is described in this chapter could be used, in practice it is generally
not possible. For a review on kinetic modelling in small animal imaging with PET, the reader
is referred to Dupont and Warwick (2009).
A new development is the use of PET to detect endogenous releases of neurotransmitters
using a stimulation paradigm. This is a great challenge since the signal changes are very weak.
Therefore, simulations are needed first to quantify the effect of different stimulus paradigms
and to estimate signal changes (Muylle et al. (2008)).
In this chapter we have looked at relatively simple models described by first order differential
equations in which the rate constants were time-independent. More complex models are
developed howevermodels with toomany parameters are not suitable for use in PET imaging.
On the other hand, simple measures like standard uptake value (SUV) or a simple ratio can
be investigated in different pathological conditions and compared with parameters derived
from kinetic modelling as described in this chapter. These very simple measures clearly have
several drawbacks and should be used with care, but they are easy to determine, which is
important when using them in a clinical setting.
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